Health Condition 1: G20- Parkinsons disease Health Condition 2: G30- Alzheimers disease Health Condition 3: G310- Frontotemporal dementia Health Condition 4: G231- Progressive supranuclear ophthalmoplegia [Steele-Richardson-Olszewski] Health Condition 5: G31- Other degenerative diseases of nervous system, not elsewhere classified
Conditions
Interventions
None listed
Sponsors
Strand Life Sciences Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: Study Arm 1.Adults aged 18 years and above 2.Adults capable of giving a written informed consent to participate 3.Individuals with confirmed diagnosis of one of the above, along with enough clinical information available (age of onset, method of diagnosis, phenotypic characteristics of the patient, information on rate of progression, clinical history) 4.Individuals from the general population of any ethnicity, sex and race 5.Ability to understand and the willingness to sign a written Informed Consent Form 6.Willingness to contribute 20 - 23 ml blood Control Arm 1.Individuals with no symptoms of the disease or prior history of any of the conditions mentioned under “study arm ? 2.Adults aged 50 years and above 3.Adults capable of giving a written informed consent to participate
Exclusion criteria
Exclusion criteria: Study and Control Group 1.Subjects with symptoms of treatable dementia like dementia due to stroke, tumor in frontotemporal region, hemorrhage in brain 2.Subjects not consenting or unable to give an informed written consent 3.Subjects who have an uncontrolled infection 4.Individuals with any acute illness or infection 5.Women who are pregnant or suspect they are pregnant and lactating mothers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome of this study will be the establishment of genetic association on a spectrum of neurodegenerative diseases in the Indian population. These studies can enable the identification of novel gene-disease associations, novel therapeutic targets, & novel biomarkers that serve as intermediate phenotypes for neurodegenerative diseases.Timepoint: At baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| The studies can enable the identification of novel gene-disease associations, novel therapeutic targets, & novel biomarkers that serve as intermediate phenotypes for neurodegenerative diseases.Timepoint: At baseline | — |
Countries
India
Contacts
Public ContactDr Vamsi Veeramachaneni
Strand Life Sciences Private Limited
Outcome results
None listed